Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.
BACKGROUND
Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone measurement for assessing cardiovascular risk for nearly 20 years.


BACKGROUND
Recent data demonstrate that apolipoprotein B (apo B) is a better measure of circulating LDL particle number (LDL-P) concentration and is a more reliable indicator of risk than LDL-C, and there is growing support for the idea that addition of apo B measurement to the routine lipid panel for assessing and monitoring patients at risk for cardiovascular disease (CVD) would enhance patient management. In this report, we review the studies of apo B and LDL-P reported to date, discuss potential advantages of their measurement over that of LDL-C, and present information related to standardization.


CONCLUSIONS
In line with recently adopted Canadian guidelines, the addition of apo B represents a logical next step to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) and other guidelines in the US. Considering that it has taken years to educate physicians and patients regarding the use of LDL-C, changing perceptions and practices will not be easy. Thus, it appears prudent to consider using apo B along with LDL-C to assess LDL-related risk for an interim period until the superiority of apo B is generally recognized.
Contois
John H
JH
Maine Standards Company, Windham, ME 04062, USA. jcontois@mainestandards.com
McConnell
Joseph P
JP
Sethi
Amar A
AA
Csako
Gyorgy
G
Devaraj
Sridevi
S
Hoefner
Daniel M
DM
Warnick
G Russell
GR
D001055:Apolipoproteins B / Q000097:blood* / Q000235:genetics; D002318:Cardiovascular Diseases / Q000097:blood* / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control; D019963:Clinical Chemistry Tests / Q000379:methods* / Q000592:standards*; D006801:Humans; D012307:Risk Factors
D001055:Apolipoproteins B